Letters
continuous administration of glucagon-like peptide 1 (GLP-1)
J ournal of Medicinal Chemistry, 2002, Vol. 45, No. 12 2365
Part 1-3 1984, 46, 297-339. (c) Scho¨n, E.; Born, I.; Demuth,
H.-U.; Faust, J .; Neubert, K.; Steinmetzer, T.; Barth, A.; Ansorge,
S. Dipeptidyl Peptidase IV in the Immune System. Biol. Chem.
Hoppe-Seyler 1991, 372, 305-311.
in subjects with NIDDM. Diabetologia 1997, 40, 205-211. (c)
Nauck, M. A.; Wollschlager, D.; Werner, J .; Holst, J . J .; Orskov,
C.; Creutzfeldt, W.; Willms, B. Effects of subcutaneous glucagon-
like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
Diabetologia 1996, 39, 1546-1553. (d) Drucker, D. J . Biological
actions and therapeutic potential of the glucagon-like peptides.
Gastroenterology 2002, 122 (2), 531-544.
(22) For comprehensive reviews on DPP-IV inhibitors, please see the
following. (a) Villhauer, E. B.; Coppola, G. M.; Hughes, T. E.
DPP-IV inhibition and Therapeutic Potential. Annu. Rep. Med.
Chem. 2001, 36, 191-200. (b) Augustyns, K.; Bal, G.; Thonus,
G.; Belyaev, A.; Zhang, X. M.; Bollaert, W.; Lambeir, A. M.;
Durinx, C.; Goossens, F.; Haemers, A. The Unique Properties
of Dipeptidyl-Peptidase IV (DPP-IV/CD26) and the Therapeutic
Potential of DPP-IV Inhibitors Curr. Med. Chem. 1999, 6, 311-
327. (c) Snow, R. J .; Bachovchin, W. W. Boronic acid inhibitors
of dipeptidyl peptidase IV; a new class of immunosuppressive
agents. Adv. Med. Chem. 1995, 3, 149-177.
(23) J enkins, P. D.; J ones, D. M. DP-IV-serine protease inhibitors.
Patent WO 95/15309, J une 5, 1995.
(24) Ashworth, D. M.; Atrash, B.; Baker, G. R.; Baxter, A. J .; J enkins,
P. D. 2-Cyanopyrrolidides as potent, stable inhibitors of dipep-
tidyl peptidase IV. Bioorg. Med. Chem. Lett. 1996, 6 (10), 1163-
1166.
(25) Li, J .; Wilk, E.; Wilk, S. Aminoacylpryyolidine-2-nitriles: Potent
and stable inhibitors of dipeptidyl-peptidase IV (CD26). Arch.
Biochem. Biophys. 1995, 323 (1), 148-154.
(26) Ashworth, D. M.; Atrash, B.; Baker, G. R.; Baxter, A. J .; J enkins,
P. D. 4-Cyanothiazolidides as very potent, stable inhibitors of
dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. 1996, 6 (22),
2745-2748.
(27) Villhauer, E. B. N-(Substituted glycly)-2-cyanopyrrolidides,
Pharmaceutical compositions containing them and their use in
inhibiting dipeptidyl peptidase-IV. U.S. Patent 6,011,155, J anu-
ary 4, 2000.
(28) The SAR of N-substituted glycine-2-(S)-cyanopyrrolidines as
DPP-IV inhibitors will be presented in a full report in due course.
(29) Hughes, T. E.; Mone, M. D.; Russell, M. E.; Weldon, S. C.;
Villhauer, E. B. NVP-DPP728 (1-[[[2-[(5-Cyanopyridin-2-yl)-
amino]acetyl]-2-cyano-(S)-pyrrolidine), a Slow-Binding Inhibitor
of Dipeptidyl Peptidase IV. Biochemistry 1999, 36, 111597-
11603.
(30) (a) Villhauer, E. B.; Anderson, R. C.; Balkan, B.; Barilla, D.;
Brinkman, J . A.; Dunn, E.; Dunning, B.; Graham, E. D.; Gu, H.
H.; Gutierrez, C. M.; Hamilton, B. H.; Kwasnik, L. A.; Li, X.;
Mangold, B. L.; Maniara, W. M.; Miserendino-Molteni, R.; Mone,
M.; Naderi, G. B.; Ramos, K. L.; Russell, M. E.; Rothenberg, T.
L.; Tullman, R. H.; Valentin, M.; Walter, R. E.; Weldon, S. C.;
Hughes, T. E. N-Substituted glycyl 2-cyanopyrrolidines as a new
family of DPP-IV inhibitor and their potential use in type 2
diabetes, Presented at the 221st National Meeting of the
American Chemical Society, San Diego, 2001; Abstract MEDI-
343. (b) Brinkman, J . A.; Villhauer, E. B.; Naderi, G. B.; Hughes,
T. E.; Mone, M.; Russell, M. E.; Weldon, S. C. Design and
synthesis of N-substituted glycyl 2-cyanopyrrolidines as a new
class of DPP-IV inhibitors. Presented at the 222nd National
Meeting of the American Chemical Society, Chicago, Il, 2001;
Abstract MEDI-39.
(31) Zuckermann, R. N.; Martin, E. J .; Spellmeyer, D. C.; Stauber,
G. B.; Shoemaker, K. R.; Kerr, J . M.; Gianine, M.; Figliozzi, D.
A.; Goff, M. A.; Siani, M. A.; Simon, R. J .; Banville, S. C.; Brown,
E. G.; Wang, L.; Richter, L. S.; Moos, W. H. Discovery of
nanomolar ligands for 7-transmembrane G-protein-coupled re-
ceptors from a diverse N(substituted)glycine peptoid library. J .
Med. Chem. 1994, 37, 2678-2685.
(32) Experimental data for individual compounds from tandem solid-
phase/solution-phase library can be obtained from Supporting
Information.
(13) (a) Wettergren, A.; Schjoldager, B.; Martensen, P. E.; Myhre,
J .; Christiansen, J .; Holst, J . J . Truncated GLP-1 (proglucagon
72-107 amide) inhibits gastric and pancreatic functions in man.
Dig. Dis. Sci. 1993, 38, 665-673. (b) Nauck, M. A.; Niederereich-
holz, U.; Ettler, R.; Holst, J . J .; Orskov, C.; Ritzel, R.; Schmigel,
W. H. Glucagon-like peptide-1 inhibition of gastric-emptying
outweighs its insulinotropic effects in healthy humans. Am. J .
Physiol. 1997, 273, E981-E988. (c) Nauck, M. A. Is GLP-1 an
incretin hormone? Diabetologia 1999, 42, 373-379. (d) Egan,
J .; Clocquet, A. R.; Elahi, D. The Insulinotropic Effect of Acute
Exendin-4-Administered to Humans: Comparison of Non-
diabetic State to Type 2 Diabetes. J . Clin. Endocrinol. Metab.
2002, 87 (3), 1282-1290.
(14) (a) Habener, J . F. Glucagonlike peptide-1 agonist stimulation
of â-cell growth and differentiation. Curr. Opin. Endocrinol.
Diabetes 2001, 8 (2), 74-81. (b) Ling, Z.; Wu, D.; Zambre, Y.;
Flamez, D.; Drucker, D. J .; Pipeleers, D. G.; Schuit, F. C.
Glucagon-like peptide 1 receptor signaling influences topography
of islet cells in mice. Virchows Arch. 2001, 438 (4), 382-387. (c)
Aspelun, F.; Egan, J . M.; Slezak, L. A.; Sritharan, K. C.; Elahi,
D.; Andersen, D. K. Glucagon-like peptide-1 and exendin-4
improve glucose tolerance and induce islet cell growth in
pancreatitis in rats. Surg. Forum 2000, 51, 40-42. (d) Kemp,
D. M.; Habener, J . F.; Insulinotropic hormone glucagon-like
peptide 1 (GLP-1) activation of insulin gene promoter inhibited
by p38 mitogen-activated protein kinase. Endocrinology 2001,
142 (3), 1179-1187. (e) Parkes, D. G.; Pittner, R.; J odka, C.;
Smith, P.; Young, A. Insulinotropic actions of exendin-4 and
glucagon-like peptide-1 in vivo and in vitro. Metab., Clin. Exp.
2001, 50 (5), 583-589.
(15) Flint, A.; Raben, A.; Ersboll, A. K.; Holst, J . J .; Astrup, A. The
effect of physiological levels of glucagon-like peptide-1 on ap-
petite, gastric emptying, energy and substrate metabolism in
obesity. Int. J . Obes. 2001, 25, 781-792.
(16) (a) Doyle, M. E.; Egan, J . M. Glucagon-like peptide-1. Recent
Prog. Horm. Res. 2001, 56, 377-399. (b) Villanueva-Pen˜acarrillo,
M. L.; Puente, J .; Redondo, A.; Clemente, F.; Valverde, I. Effect
of GLP-1 treatment on GLUT2 and GLUT4 expression in type
1 and type 2 rat diabetic models. Endocrine 2001, 15 (2), 241-
248.
(17) J uana, F.; Valdeolmillos, M. Glucose-dependent stimulatory
effect of glucagon-like peptide 1(7-36) amide on the electrical
activity of pancreatic â-cells recorded in vivo. Diabetes 1999, 48
(4), 754-757.
(18) These nonsubstrate DPP-IV inhibitors provide low micromolar
IC50’s and, except in refs 3a and 3b, contain a protonatable
amine. (a) Shimazawa, R.; Takayama, H.; Kato, F.; Kato, M.;
Hashimoto, Y. Nonpeptide small-molecular inhibitors of dipep-
tidyl peptidase IV; N-phenylphthalimide analogs. Bioorg. Med.
Chem. Lett. 1999, 9, 559-562. (b) Miyachi, H.; Kato, M.; Kato,
F.; Hashimoto, Y. Novel potent nonpeptide aminopeptidase N
inhibitors with a cyclic imide skeleton. J . Med. Chem. 1998, 41
(3), 263-265. (c) Yamada, M.; Okagaki, C.; Higashijima, T.;
Tanaka, S.; Ohnuki, T.; Sugita, T. A potent dipeptide inhibitor
of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. 1998, 8,
1537-1540. (d) Coppola, G. M.; Zhang, Y. L.; Schuster, H. F.;
Russell M. E.; Hughes T. E. 1-Aminomethylisoquinoline-4-
carboxylates as novel dipeptidylpeptidase IV inhibitors. Bioorg.
Med. Chem. Lett. 2000, 10, 1555-1558.
(19) Irreversible oligopeptides with the N-terminal X-Pro-X se-
quence (low micromolar IC50). Rahfeld, J .; Schierhorn, M.;
Hartrodt, B.; Neubert, K.; Heins, J . Are Diprotin A and (Ile-
Pro-Ile) and Diprotin B (Val-Pro-Leu) Inhibitors or Substrates
of Dipeptidyl Peptidase IV? Biochim. Biophys. Acta 1991, 1076,
314-316.
(20) Suicide substrate (latent quinoniminium methide electrophile)
large cyclopeptide. Nguyen, C.; Blanco, J .; Mazaleyrat, J . P.;
Krust, B.; Callebaut, C.; J acotot, E.; Hovanessian, A. G.; Wak-
selman, M. Specific and Irreversible Cyclopeptide Inhibitors of
Dipeptidyl Peptidase IV Activity of the T-Cell Activation Antigen
CD26. J . Med. Chem. 1998, 41, 2100-2110.
(21) (a) Heins, J .; Welker, P.; Scho¨nlein, C.; Born, I.; Hartrodt, B.;
Neubert, K.; Tsuru, D.; Barth, A. Mechanism of Proline-Specific
Proteinases; (I) Substrate Specificity of Dipeptidyl Peptidase IV
from Pig Kidney and Prolein-Specific Endopeptidase from Fla-
vobacterium meningosepticum. Biochim. Biophys. Acta 1988,
954, 161-169. (b) Barth, A.; Heins, J .; Fischer, G.; Neubert, K.;
Schneeweiss, B. Dipeptidyl-peptidase IV: mechanism and speci-
ficity of the substrate cleavage. Mol. Cell. Regul. Enzyme Act.,
(33) ORTEP drawing of NVP-DPP728 (2) and atomic coordinate
information can be obtained from Supporting Information.
(34) PPCE and DPP-II are the standard enzymes in DPP-IV selectiv-
ity studies. (a) Belyaev, A.; Zhang, X.; Augustyns, K.; Lambeir,
A. M.; De Meester, I.; Vedernikova, I.; Scharpe´, S.; Haemers, A.
Structure-Activity Relationship of Diaryl Phosphonate Esters
as Potent Irreversible Dipeptidyl Peptidase IV Inhibitors. J .
Med. Chem. 1999, 42, 1041-1052. Other related enzymes are
quite new, and their assays are not yet well validated. (b) Sedo,
A.; Malik, R. Dipeptidyl peptidase IV-like molecules: homologous
proteins or homologous activities. Biochim. Biophys. Acta 2001,
1550, 107-116.
(35) (a) Rothenberg, P.; Kalbag, J .; Smith, H. T.; Gingerich, R.;
Nedelman, J .; Villhauer, E.; McLeod, J .; Hughes, T. Treatment
with
a DPP-IV Inhibitor, NVP-DPP728, Increases Prandial
Intact GLP-1 Levels and Reduces Glucose Exposure in Humans.
Diabetes 2000, 49 (1), A39. (b) Ahre´n, B.; Sinonsson, E.; Larsson,
H.; Landin-Oisson, M.; Torgeirsson, H.; Jansson, P. A.; Sandqvist,
M.; Båvenholm, P.; Efendic, S.; Eriksson, J . W.; Dickinson, S.;
Holmes, D. Inhibition of dipeptidyl peptidase IV improves
metabolic control over a 4 week study period in type 2 diabetes.
Diabetes Care 2002, 25 (5), 869-875.
J M025522Z